TORONTO, ONTARIO--(Marketwire - August 20, 2008) - Lorus Therapeutics Inc, (TSX: LOR)(AMEX: LRP) (“Lorus”), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced publication by the California Cancer Consortium of a paper entitled “Identification of F-box/LLR-repeated Protein 17 a Potential Useful Biomarker for Breast Cancer Therapy” (Xiao et al. Cancer Genomics and Proteomics 2008; 5: 151-160). This presents results of proteomics studies from a clinical trial of LOR-2040 in combination with Capecitabine in patients with advanced metastatic breast cancer.
